NEW YORK, December 30, 2025, 14:30 ET — Regular session
- Kymera shares were lower in afternoon trading, underperforming a softer biotech tape.
- The stock remains in focus after December trial news and a large equity raise, with 2026 milestones ahead.
Shares of Kymera Therapeutics fell about 3% to $77.94 in afternoon trading on Tuesday, lagging a broader biotech dip. The SPDR S&P Biotech ETF was down about 1.4%, while the iShares Nasdaq Biotechnology ETF slipped about 1.1%.
The pullback matters because Kymera has been one of the sector’s higher-volatility names this month, after a surge tied to new clinical data and a subsequent stock sale that increased its share count.
With most of its next major readouts still far off, investors have been quick to reprice the stock around financing levels, regulatory signals and shifts in biotech risk appetite heading into year-end positioning.
Kymera is a clinical-stage biotech developing “degrader” drugs — small molecules designed to tag disease-driving proteins for removal by the body’s normal disposal system, a strategy known as targeted protein degradation.
Earlier this month, Kymera said its once-daily oral STAT6 degrader KT-621 showed positive Phase 1b results in atopic dermatitis, and management pointed to a path into mid-stage studies. “The BroADen study results exceeded our highest expectations,” CEO Nello Mainolfi said in the company’s release. 1
Investors have focused on whether an oral option could eventually compete in “Type 2” inflammatory diseases — a category where injectable biologics such as dupilumab (Dupixent) have been a standard of care.
Kymera also closed an upsized underwritten public offering in mid-December, selling 8.05 million shares at $86 each and reporting gross proceeds of about $692 million before fees. The stock was trading roughly 9% below that $86 deal price on Tuesday. 2
Days earlier, Kymera said the U.S. Food and Drug Administration granted Fast Track designation to KT-621 for moderate-to-severe atopic dermatitis. Fast Track is a regulatory program intended to speed development and review for drugs aimed at serious conditions and unmet needs, though it does not guarantee approval. 3
Tuesday’s decline came as biotech shares broadly softened, a backdrop that can amplify moves in single-name drug developers that lack near-term revenue and depend on capital markets to fund trials.
Before the next cluster of company updates, investors are likely to watch for signals on cash burn, trial execution and whether Kymera can stabilize after the December financing. The company has not confirmed its next earnings date, but MarketBeat and Zacks list late February 2026 as an expected reporting window. 4
